TY - JOUR
T1 - Point prevalence study of antimicrobial use among hospitals across Botswana; findings and implications
AU - Anand Paramadhas, Bene D.
AU - Tiroyakgosi, Celda
AU - Mpinda-Joseph, Pinkie
AU - Morokotso, Mathudi
AU - Matome, Matshediso
AU - Sinkala, Fatima
AU - Gaolebe, Mavis
AU - Malone, Brighid
AU - Molosiwa, Emmanuel
AU - Shanmugam, Muthu Guhan
AU - Raseatlholo, Gogaisa Pearl
AU - Masilo, Joyce
AU - Oyeniran, Yomi
AU - Marumoloa, Stella
AU - Maakelo, Omphile Glory
AU - Katjakae, Ishmael
AU - Kgatlwane, Joyce
AU - Godman, Brian
AU - Massele, Amos
N1 - Publisher Copyright:
© 2019, © 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2019/7/3
Y1 - 2019/7/3
N2 - Objective: There is an urgent need to undertake Point Prevalence Surveys (PPS) across Africa to document antimicrobial utilisation rates given high rates of infectious diseases and growing resistance rates. This is the case in Botswana along with high empiric use and extended prophylaxis to prevent surgical site infections (SSIs) Method: PPS was conducted among all hospital sectors in Botswana using forms based on Global and European PPS studies adapted for Botswana, including rates of HIV, TB, malaria, and malnutrition. Quantitative study to assess the capacity to promote appropriate antibiotic prescribing. Results: 711 patients were enrolled with high antimicrobial use (70.6%) reflecting an appreciable number transferred from other hospitals (42.9%), high HIV rates (40.04% among those with known HIV) and TB (25.4%), and high use of catheters. Most infections were community acquired (61.7%). Cefotaxime and metronidazole were the most prescribed in public hospitals with ceftriaxone the most prescribed antimicrobial in private hospitals. Concerns with missed antibiotic doses (1.96 per patient), high empiric use, extended use to prevent SSIs, high use of IV antibiotics, and variable infrastructures in hospitals to improve future antibiotic use. Conclusion: High antibiotic use reflects high rates of infectious diseases observed in Botswana. A number of concerns have been identified, which are being addressed.
AB - Objective: There is an urgent need to undertake Point Prevalence Surveys (PPS) across Africa to document antimicrobial utilisation rates given high rates of infectious diseases and growing resistance rates. This is the case in Botswana along with high empiric use and extended prophylaxis to prevent surgical site infections (SSIs) Method: PPS was conducted among all hospital sectors in Botswana using forms based on Global and European PPS studies adapted for Botswana, including rates of HIV, TB, malaria, and malnutrition. Quantitative study to assess the capacity to promote appropriate antibiotic prescribing. Results: 711 patients were enrolled with high antimicrobial use (70.6%) reflecting an appreciable number transferred from other hospitals (42.9%), high HIV rates (40.04% among those with known HIV) and TB (25.4%), and high use of catheters. Most infections were community acquired (61.7%). Cefotaxime and metronidazole were the most prescribed in public hospitals with ceftriaxone the most prescribed antimicrobial in private hospitals. Concerns with missed antibiotic doses (1.96 per patient), high empiric use, extended use to prevent SSIs, high use of IV antibiotics, and variable infrastructures in hospitals to improve future antibiotic use. Conclusion: High antibiotic use reflects high rates of infectious diseases observed in Botswana. A number of concerns have been identified, which are being addressed.
KW - Antibiotics
KW - Botswana
KW - antimicrobial resistance
KW - antimicrobial stewardship programs
KW - antimicrobial utilization
KW - drugs and therapeutic committees
KW - hospitals
KW - point prevalence studies
UR - http://www.scopus.com/inward/record.url?scp=85068514937&partnerID=8YFLogxK
U2 - 10.1080/14787210.2019.1629288
DO - 10.1080/14787210.2019.1629288
M3 - Article
C2 - 31257952
AN - SCOPUS:85068514937
SN - 1478-7210
VL - 17
SP - 535
EP - 546
JO - Expert Review of Anti-Infective Therapy
JF - Expert Review of Anti-Infective Therapy
IS - 7
ER -